U S District Court Issues Decision On REGENXBIO And University Of Pennsylvania NAV® Technology Patent Infringement Lawsuit menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
U S District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced that the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE®.
ROCKVILLE, Md., Nov. 7, 2023 /PRNewswire/ REGENXBIO Inc. today announced it will participate the following upcoming investor conferences:
Stifel 2023 Healthcare Conference Fireside Chat Date:.
REGENXBIO to Participate in Upcoming Investor Conferences lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.